Workflow
募集资金规范使用
icon
Search documents
浙江海森药业股份有限公司
Group 1 - The company held its 14th meeting of the third board of directors on August 13, 2025, with all seven directors present, ensuring compliance with relevant laws and regulations [3][4]. - The board approved the 2025 semi-annual report and its summary, which accurately reflects the company's operational status and financial information for the first half of 2025 [4][6]. - The board also approved a special report on the storage and use of raised funds for the first half of 2025, confirming compliance with regulations and no misuse of funds [6][7]. Group 2 - The company proposed amendments to its Articles of Association and related rules to enhance governance structure and align with the latest legal requirements, including the adjustment of internal supervisory bodies [9][10]. - The amendments require approval from the second extraordinary general meeting of shareholders in 2025, with the management authorized to complete necessary registration and filing procedures [9][10]. - The board approved several governance system revisions, including the investment management system and the guarantee management system, which will also be submitted for shareholder approval [12][15]. Group 3 - The board passed multiple resolutions to revise various governance documents, including the independent director work system and the internal audit system, all pending shareholder approval [27][41]. - The company aims to ensure that its governance practices remain in sync with regulatory requirements and improve operational mechanisms [12][39].